All In Biotech

Drug Trial Radar · NCT06660394

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults With Dravet Syndrome

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

108

Actual

Start

Sep 25, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Longboard PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.

Conditions

  • Dravet Syndrome

Interventions

  • LP352Drug

    LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube

  • PlaceboDrug

    Participants will be administered with matching placebo orally or through G-tube/ PEG tube

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency Percent Change in Countable Motor Seizures During Treatment Compared to BaselineTime frame: Baseline and up to 15 Weeks

Locations

105 sites in 18 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital - Cardiology Clinic

    Little Rock, Arkansas

  • Children's Hospital Los Angeles (CHLA)

    Los Angeles, California

  • University of California Los Angeles (UCLA) - David Geffen School of Medicine - Global Health Pro...

    Los Angeles, California

  • Stanford University - Stanford School of Medicine - Pulmonary and Cystic Fibrosis Center

    Palo Alto, California

  • UCSF Benioff Children's Hospitals - San Francisco

    San Francisco, California

  • Children's Hospital Colorado - Heart Institute

    Aurora, Colorado

  • Children's National Hospital - Children's National Heart Center

    Washington D.C., District of Columbia

  • NW FL Clinical Research Group, LLC

    Gulf Breeze, Florida

  • Nicklaus Children's Hospital (Miami Children's Hospital)

    Miami, Florida

  • Research Institute of Orlando LLC

    Orlando, Florida

  • Pediatric Epilepsy & Neurology Specialists (PENS)

    Tampa, Florida

  • Rare Disease Research, LLC. (RDR)

    Atlanta, Georgia

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Northwestern University - Ann & Robert H. Lurie Children's Hospital of Chicago - Center for Cance...

    Chicago, Illinois

  • Mid-Atlantic Epilepsy and Sleep Center - Bethesda

    Bethesda, Maryland

  • Mayo Clinic - Children's Center - Rochester

    Rochester, Minnesota

  • Barnabas Health - Institute of Neurology and Neurosurgery

    Livingston, New Jersey

  • Northeast Regional Epilepsy Group - Morristown

    Morristown, New Jersey

  • NYU Langone Health-NYU Comprehensive Epilepsy Center

    New York, New York

  • Oregon Health & Science University - Blood Brain Barrier and Neuro-Oncology Program

    Portland, Oregon

  • Le Bonheur Children's Hospital - Outpatient Center

    Memphis, Tennessee

  • Child Neurology Consultants of Austin - Austin

    Austin, Texas

  • Cook Children's Jane and John Justin Neurosciences Center

    Fort Worth, Texas

  • The University of Texas Medical School at Houston - UT Gastroenterology

    Houston, Texas

  • MultiCare Health System

    Tacoma, Washington

  • Prince of Wales Hospital (POWH)

    Randwick, New South Wales, Australia

  • Sydney Children's Hospital - Randwick

    Randwick, New South Wales, Australia

  • The Children's Hospital-Westmead - Heart Centre for Children

    Westmead, New South Wales, Australia

  • Royal Brisbane and Women's Hospital (RBWH)

    Brisbane, Queensland, Australia

  • Queensland Children's Hospital (Lady Cilento Children's Hospital)

    Brisbane, Queensland, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • The Royal Children's Hospital (RCH) Melbourne

    Parkville, Victoria, Australia

  • Universitair Ziekenhuis Antwerpen (UZA)

    Edegem, Antwerp, Belgium

  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

    Leuven, Flemish Brabant, Belgium

  • Universidade de Sao Paulo (USP) - Hospital das Clinicas da Faculdade de Medicina (HCFMUSP) - Inst...

    São Paulo, Brazil

  • Instituto de Neurologia de Curitiba (INC)

    Curitiba, Paraná, Brazil

  • Moinhos de Vento Hospital (Hospital Moinhos de Vento) (HMV)

    Porto Alegre, Rio Grande do Sul, Brazil

  • Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS) - Instituto Do Cerebro Do Rio Grand...

    Porto Alegre, Rio Grande do Sul, Brazil

  • Universidade Estadual de Campinas (UNICAMP) - Hospital das Clinicas (HC)

    Campinas, São Paulo, Brazil

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.